We previously reported the expression of angiopoietin receptor Tie2 on human neutrophils. Both angiopoietins (Ang1 and Ang2) induce platelet activating factor (PAF) synthesis from endothelial cells (ECs) and neutrophils. Both angiopoietins can also modulate EC viability and since PAF can promote pro-survival activity on neutrophils, we addressed whether Ang1 and/or Ang2 could modulate neutrophil viability. Neutrophils were isolated from venous blood of healthy volunteers and neutrophil viability was assessed by flow cytometry using apoptotic and necrotic markers (annexin-V and propidium iodide (P.I.), respectively). Basal neutrophil viability from 0 to 24 h post-isolation decreased from 98% to ≈ 45%. Treatment with anti-apoptotic mediators such as interleukin-8 (IL-8; 25 nM) and PAF (100 nM) increased neutrophil basal viability by 34 and 26% (raising it from 43 to 58 and 55%) respectively. Treatment with Ang1 (0.001-50 nM) increased neutrophil viability by up to 41%, while Ang2 had no significant effect. Combination of IL-8 (25 nM) or PAF (100 nM) with Ang1 (10 nM) further increased neutrophil viability by 56 and 60% respectively. We also observed that Ang1, but not Ang2 can promote IL-8 release and that a pretreatment of the neutrophils with blocking anti-IL-8 antibodies inhibited the anti-apoptotic effect of IL-8 and Ang1 by 92 and 81% respectively. Pretreatment with a selective PAF receptor antagonist (BN 52021), did abrogate PAF pro-survival activity, without affecting Ang1induced neutrophil viability. Our data are the first ones to report Ang1 pro-survival activity on neutrophils, which is mainly driven through IL-8 release. j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / b b a m c r 359 E. Dumas et al. / Biochimica et Biophysica Acta 1823 (2012) 358-367
Introduction
Angiopoietins (Ang1 and Ang2) are growth factors structurally related, and contributing to angiogenesis upon binding to Tie2 receptor [1] . Ang1 is known as a Tie2 agonist capable of inducing EC migration and proliferation [2] [3] [4] [5] . In addition, Ang1 promotes pericyte recruitment to the newly formed vessels, therefore leading to the maturation and stabilization of the vasculature [6, 7] . Furthermore, Ang1 has the capacity to reduce apoptosis of many cellular types such as EC, cardiomyocytes and mesenchymal stem cells [8] [9] [10] [11] . This activity can lead to a protective role of Ang1 in acute inflammatory conditions such as in lung injury, and in chronic diseases such as cardiac remodeling where Ang1 improves cardiomyocytes survival and reduces cardiac hypertrophy [12, 13] . In contrast, Ang2 was initially reported as a Tie2 antagonist, inducing vascular permeability and EC apoptosis, therefore, leading to the promotion of a pro-inflammatory environment and the destabilization of pre-existing vasculature [14, 15] . However, mounting evidence demonstrates that Ang2 could also have agonistic properties by being able to induce Tie2 phosphorylation, EC chemotaxis and in vitro tubule capillary-like formation [16] [17] [18] [19] . In previous studies, we reported that both angiopoietins exert pro-inflammatory activities on ECs by their capacity to stimulate PAF synthesis and P-selectin translocation, therefore leading to neutrophil adhesion onto activated ECs and transmigration [20] [21] [22] . Furthermore, angiopoietins can also modulate cytokine activities in ECs, for instance, at low concentrations, Ang2 is a priming factor for tumor necrosis factor-α (TNF-α) [23] and both Ang1 and Ang2 have been reported to potentiate VEGF-induced angiogenesis in a mouse cornea model [1] .
We also reported the expression of Tie2 receptor on human neutrophils, and that both angiopoietins can promote pro-inflammatory activities on neutrophils [22] . Ang1 and Ang2 support neutrophil PAF synthesis, activation of CD11b/CD18 (β 2 -integrin), adhesion and migration [22, 24] . In addition, angiopoietins can also enhance the activities of pro-inflammatory mediators, for instance, pretreatment with Ang1 and/or Ang2 potentiates IL-8-induced neutrophil migration [24] .
Neutrophil lifespan is relatively short, ranging from 8 to 20 h in blood circulation and up to few days in perivascular tissues [25] [26] [27] . Neutrophils are the primary leukocytes being recruited at inflammatory sites and promote a range of pro-inflammatory activities, namely by their capacity to release various chemokines and cytokines, including VEGF, TNF-α, IL-1, IL-8 and PAF [28, 29] . Neutrophils can also secrete catalytic enzymes (metalloproteinases, lysosymes), which contribute to extracellular matrix degradation and elimination of pathogens [29, 30] . Increasing neutrophil viability can prolong and enhance the inflammatory response, thus, contributing to the development and progression of multiple vascular-associated diseases such as systemic inflammatory response syndrome (SIRS), tumor growth, ischemia/ reperfusion injury and rheumatoid arthritis (RA) [26, [31] [32] [33] [34] [35] .
For instance, it has been reported that the expression of both angiopoietins and members of Tie-receptor family (Tie1 and Tie2) is increased in patients suffering from RA, and that the corresponding expression is not limited to vascular cells, but also overexpressed in stromal cells and in the synovial lining [36] . Such overexpression could lead to the development of pathological angiogenesis, which can be inhibited by the blockade of Ang/Tie ligand-receptor system [37] . In addition, since RA is characterized as a chronic inflammatory disease, angiopoietins could contribute to the inflammatory process through their capacity to promote neutrophil-mediated proinflammatory responses, namely through PAF and IL-8 participation [22, 24, 38, 39] .
PAF is a bioactive lipid that derivates from arachidonic acid metabolism acting through the stimulation of a G-protein-coupled receptor (PAFR). This potent pro-inflammatory mediator is involved in inflammation, reproduction, angiogenesis and tumor growth metastasis [40] . PAF activates and is produced by many inflammatory cells including ECs, platelets, monocytes, lymphocytes and neutrophils. In addition, in function of the cell type, PAF promotes many pro-inflammatory activities such as platelet aggregation and modulation of cell viability [41] . For instance, PAF promotes apoptosis on hepatocytes and neurons, whereas it can prolong cell viability of various leukocytes, including neutrophils [40, 42] .
IL-8 was first described as a monocyte-derived neutrophil chemotactic factor (MDNCF) [43] [44] [45] , and subsequently reported for being synthesized by ECs, fibroblasts and keratinocytes [46, 47] . IL-8 is a major pro-inflammatory mediator, acting predominantly on neutrophils where it induces respiratory burst [48] , generation of superoxide and hydrogen peroxide [49] , cellular reorganization [49] , secretion of catalytic enzymes (metalloproteinases, lysosymes) [50] , synthesis of bioactive lipids [51] , translocation and activation of adhesion molecules [52] , chemotaxis [53] and pro-survival activity [54] . IL-8 is also involved in the development of various pathological conditions, such as acute respiratory distress syndrome (ARDS), ischemia/reperfusion injury, tumor growth and metastasis [46, 54] .
Since both angiopoietins can modulate endothelial cell survival [10, 11, 17, [55] [56] [57] and induce PAF synthesis [21, 22] which supports neutrophil viability [42] , and that both angiopoietins can modulate IL-8 chemotactic activity on neutrophils [24] , we thus wanted to assess whether Ang1 and/or Ang2 can modulate neutrophil viability, and if so, delineate the potential contribution of specific cytokines being synthesized and released by the neutrophils.
Material and methods

Neutrophil isolation and purification
Human venous blood was obtained from consent healthy donors free from medication for at least 10 days prior to the experiments and in accordance with the guidelines of the Montreal Heart Institute's ethical committee. Neutrophils were isolated as described previously [22, 24, 58] . Neutrophils were then resuspended in RPMI medium (Lonza, Basel, Switzerland) supplemented with 25 mM Hepes (N-2hydroxyethylpiperazine-N′-2-ethanesulfonic acid) and 1% penicillin/ streptomycin. At least 95% of isolated cells were neutrophils as determined by staining with Kwik Diff solutions according to the manufacturer's instructions (Thermo Fisher Scientific, Kalamazoo, MI, USA) and viability was found to be greater than 98% as assessed by Trypan blue dye exclusion assay [59] .
Assessment of viability, apoptosis and necrosis
Neutrophils were incubated in 24-well plates (Becton Dickinson, San Jose, CA, USA) at 5 × 10 6 cells/well for different periods of time (0-24 h) at 37°C and treated with various agonists: Ang1 and Ang2 (R&D Systems, Minneapolis, MN, USA), IL-8 (Peprotech, Rocky Hill, NJ, USA) and methylcarbamyl-PAF C-16 (PAF; Cayman Chemical, Ann Arbor, MI, USA) in RPMI medium supplemented with 10% human serum (Millipore, Billerica, MA, USA). In some experiments, neutrophils were preincubated with a secreted phospholipase A 2 (sPLA 2 ) inhibitor, 12-epi-scalaradial (Biomol, Plymouth Meeting, PA, USA), a cytosolic PLA 2 (cPLA 2 ) inhibitor, AACOCF 3 (Cayman Chemical), a PAF receptor antagonist, BN 52021 (Sigma-Aldrich, St. Louis, MO, USA), a goat polyclonal blocking anti-human Tie2 antibody (R&D Systems, #AF313), a goat polyclonal blocking anti-human IL-8 antibody (R&D Systems, #AB-208-NA) or control IgG isotype for 30 min to 2 h prior to the addition of selected agonists. Viability was measured by flow cytometry using annexin-V-fluorescein isothiocyanate (FITC) and P.I. (Becton Dickinson) as previously described [60, 61] . Briefly, neutrophils (1 × 10 6 cells/50 μl) were rinsed with PBS, centrifuged (900 g, 7 min at 4°C), resuspended in annexin-V binding buffer (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl 2 , pH 7.4) (Becton Dickinson) and incubated in the dark for 15 min at room temperature in the presence of 2.5 μl of annexin-V-FITC (20 μg/ml in aqueous buffered solution containing BSA and 0.09% sodium azide) and 5 μl of P.I. (50 μg/ml in PBS, pH 7.4) (PharMingen, Becton Dickinson). Flow cytometry analyses (15 000 events per tube) were performed using a flow cytometer with a 488 nm wavelength argon laser (Coulter EPICS XL, Beckman Coulter, Brea, CA, USA). Intact neutrophils were selected according to size and granularity. Cells negative for both annexin-V and P.I. were considered as viable (annexin-V − /P.I. − ), annexin-V-positive and P.I.-negative cells were considered as early apoptotic (annexin-V + /P.I. − ) and cells positive for both markers were considered as necrotic and/or in late apoptotic phase (annexin-V + /P.I. + ).
Morphological assessment of neutrophil apoptosis
Viability was also assessed by morphological observations as previously described [27] . Neutrophils (5 × 10 5 cells/condition) were cytocentrifuged, fixed and stained for 30 s with hematoxylin QS (Vector Laboratories, Burlingame, CA, USA). Neutrophils were examined under oil immersion light microscopy at 400× magnification. Cells in five random fields per condition were analyzed and apoptotic/necrotic cells were characterized by condensed and darkly stained nuclei. At least 400 neutrophils were counted per condition. Flow cytometry and morphological assessment gave similar results in regard to neutrophil viability.
Neutrophil chemotactic activity
In vitro chemotactic assays were performed in Transwell-96 well permeable supports. The top and the bottom well were separated by a porous polycarbonate membrane filter (3 μm pore size) (Corning Life Science, Corning, NY) as previously described [62, 63] . Briefly, the bottom wells were loaded with RPMI containing PBS, IL-8 (25 nM) or fMLP (0.1-10 μM) to a final volume of 230 μl. The top wells were loaded with neutrophils (10 7 cells/ml; 80 μl from a RPMI suspension). In function of the experiments, neutrophils were freshly added postisolation or pretreated for 24 h with PBS or Ang1 (10 nM) prior to the chemotactic assay. The Transwell-96 well permeable supports were incubated at 37°C for 1 h in a humidified incubator in the presence of 5% CO 2 . At the end of the incubation period, the supernatant from the bottom wells was collected, and a count of migrating neutrophils was assessed with an Amnis ImageStream system.
Statistical analysis
Results from each experiment are the mean of cumulative independent experiments from the blood of at least three independent donors, and expressed as the mean ± SEM. Comparisons were made by analysis of variance (ANOVA) followed by a Dunnett's test. Differences were considered significant at p values ≤ 0.05.
Results
Ang1, but not Ang2, promotes neutrophil viability
It has been reported that Ang1 and Ang2 modulate EC survival while PAF increases neutrophil viability [10, 11, 17, 42, 56, 57, 64] . On our side, we have reported that both angiopoietins induce PAF synthesis in neutrophils [22] . Thus, we sought to determine whether angiopoietins could modulate neutrophil viability and the potential role of PAF. In a first series of experiments we assessed the survival rate of neutrophils on a 24-hour period. Upon neutrophil isolation, the viability of the cells was ≈98% and declined time-dependently to ≈45% after 24 h. We then used PAF as a positive control to promote neutrophil viability. Upon a 24-hour incubation period, we observed a bell-shape concentration-dependent anti-apoptotic effect of PAF (1-10 000 nM) on neutrophil viability with an optimal effect being achieved at 100 nM, providing a 26% increase of neutrophil viability (raising the basal viability from 43.4 to 54.8%) (Suppl. data Fig. 1 ).
We then assessed the capacity of both angiopoietins (Ang1 and Ang2) to modulate neutrophil viability on a concentration-and timedependent manner. Treatment with Ang1 (0.001-50 nM; 0.07-3500 ng/ml) increased significantly neutrophil viability at 1, 10 and 50 nM, raising the basal viability from 43.4 to 53.3, 59.0 and 61.3% respectively (corresponding to a 23, 36 and 41% increase). Interestingly, in the current set of experiments, Ang1 at 10 nM was already more potent than PAF (100 nM) to promote neutrophil viability ( Fig. 1A) . To assess whether Ang1-mediated pro-survival activity was caused by an effect on apoptosis or necrosis, we evaluated the effect of Ang1 on neutrophil viability with two specific markers of membrane asymmetry, annexin-V-FITC (phosphatidylserine externalization; apoptosis) and P.I. (intercalating agent; necrosis). These data were further confirmed by cytologic staining and morphological assessment of neutrophil viability under optical microscopy. The beneficial effect of Ang1 on neutrophil viability is observed by its capacity to reduce the apoptotic and necrotic events. In fact, PAF and Ang1 had a similar capacity to significantly lower neutrophil apoptosis (reducing it from 38.9% to 34.1% and 29.4% respectively). In addition, PAF and Ang1 had a similar capacity to significantly lower neutrophil necrosis (reducing it from 15.9% to 8.8% and 9.7% respectively) ( Fig. 1A) . In parallel, we performed the same experiments with neutrophils from the same donors and observed that Ang2 (0.001-50 nM; 0.066-3300 ng/ml) as opposed to Ang1, had no significant effect on neutrophil viability ( Fig. 1B) . As the maximal effect mediated by Ang1 was nearly achieved at 10 nM, we elected to limit the use of Ang1 up to 10 nM for upcoming experiments.
We then treated the neutrophils with the angiopoietins (Ang1, Ang2; 1 and 10 nM) and PAF (100 nM; positive control) on a 24-hour time period to address the kinetic of Ang1-mediated anti-apoptotic activity. Treatment with Ang1 (1 and 10 nM; 70 and 700 ng/ml) provided a positive trend on neutrophil viability upon 12 h post-isolation, and the Ang1 anti-apoptotic effect was significant and maximal (10 nM) at 24 h ( Fig. 2A) . By performing a time-response kinetic, we were led to observe that Ang1 (1 and 10 nM) had a beneficial pro-survival activity by delaying the entry of neutrophils into apoptotic and necrotic phases ( respectively. In addition, treatment with PAF (100 nM) or Ang1 (1 and 10 nM) at 24 h also significantly decreased neutrophil necrosis by 45, 31 and 39% respectively ( Fig. 2C ). Since pro-survival activity of Ang1 and PAF on neutrophils was optimal at 24 h, our experiments were subsequently performed at 24 h post-isolation. The same experiments were performed in parallel with Ang2 (1 and 10 nM; 66 and 660 ng/ml). Again, we observed that Ang2 had no effect on neutrophil viability, apoptosis and necrosis from 0 to 24 h post-isolation ( Fig. 2A -C).
Ang1-mediated pro-survival activity is Tie2-dependent
In previous studies, we and other groups observed that angiopoietins could mediate their biological activities upon binding and activation of Tie2 receptor [22, 24, 65, 66] . Thus, we wanted to assess if the pro-survival activity of Ang1 is implying Tie2 participation. In the current set of experiments, neutrophils were pretreated with a goat polyclonal blocking anti-human Tie2 antibody (5, 10 or 20 μg/ml) or control goat IgG isotype (20 μg/ml) for 1 h before stimulation with PBS or Ang1 (10 nM) for an additional 23 h. Treatment with control goat IgG or with anti-Tie2 blocking antibodies (20 μg/ml) had no significant effect on basal neutrophil viability ( Fig. 3 ). Pretreatment of neutrophils with anti-Tie2 blocking antibodies reduced in a concentration-dependent manner the pro-survival activity of Ang1 with a maximal effect being achieved at 20 μg/ml (84% inhibition) ( Fig. 3 ). Pretreatment of neutrophils with anti-Tie2 blocking antibodies did not reverse Ang1 mediated anti-apoptotic activity but did abrogate Ang1-anti-necrotic activity (Fig. 3 ).
Additive effect of PAF and Ang1 on neutrophil viability
Since PAF is a neutrophil pro-survival mediator [42] , and as observed in our current study, we thus wanted to address whether both angiopoietins and PAF could cooperate on neutrophil viability. Neutrophils were treated with Ang1 (0.1-10 nM) in the presence or absence of PAF (100 nM) for 24 h. Treatment with PAF or Ang1 (1 and 10 nM) increased neutrophil viability by 26, 23 and 36% respectively ( Fig. 4 ). Combining PAF (100 nM) with Ang1 (1 and 10 nM) provided an additive effect, increasing by 48 and 60% the viability of the neutrophils (raising the basal neutrophil viability from 43.4 to 64.4 and 69.6%, respectively). Furthermore, the combination of PAF (100 nM) with Ang1 (1 and 10 nM) provided a significant increase of neutrophil survival as compared to the cells treated either with PAF (100 nM) or Ang1 (1 or 10 nM) alone ( Fig. 4 ). Neutrophils were also treated with Ang1 (0.1 nM) to assess whether PAF (100 nM) could prime an effect of Ang1 at a concentration, which by itself does not induce neutrophil viability. This latter combination did not provide an additive effect on neutrophil viability ( Fig. 4 ). In addition, treatment of neutrophils with PAF or Ang1 provided a significant decrease of apoptosis and their combination (PAF; 100 nM and Ang1; 10 nM) provided an additive capacity to decrease neutrophil apoptosis as compared to the cells treated either with PAF (100 nM) or Ang1 (10 nM) alone ( Fig. 4) . Finally, the combination of PAF (100 nM) with Ang1 (1 and 10 nM) provided a significant decrease of neutrophil necrosis as compared to the cells treated either with PAF (100 nM) or Ang1 (1 or 10 nM) alone ( Fig. 4 ).
Contribution of PAF on Ang1 pro-survival activity
In the current setting of experiments, we wanted to address if endogenous PAF is involved in Ang1 pro-survival activity on neutrophils. We thus pretreated neutrophils with a selective PAF receptor antagonist (BN 52021; 50 and 100 μM) [67, 68] , or the corresponding control vehicle (DMSO) for 1 h prior to the addition of PAF (100 nM) or Ang1 (10 nM) for an additional 23 h. Treatment with BN 52021 alone did not modulate basal neutrophil viability. In pretreatment, BN 52021 abrogated completely PAF-mediated pro-survival activity, bringing the survival rate of the neutrophil even below to the control-PBS level (Fig. 5 ). In addition, a pretreatment with BN 52021 abrogated as well the PAF-mediated anti-apoptotic effect on neutrophils ( Fig. 5 ). On the other hand, a pretreatment with BN 52021 did not modulate significantly the effect of Ang1 on neutrophil viability, apoptosis and necrosis ( Fig. 5 ). We previously reported that in ECs, both angiopoietins induce PAF synthesis through the activation of sPLA 2 -V and independently from cPLA 2 activation [21] . In function of the stimulus, both PLA 2 s can be activated to promote neutrophil PAF synthesis [69] [70] [71] [72] [73] . We thus pretreated the neutrophils with a sPLA 2 inhibitor (scalaradial; up to 20 μM) [21, 74, 75] , a cPLA 2 inhibitor (AACOCF 3 ; up to 20 μM) [21, [74] [75] [76] or their corresponding control vehicles (DMSO or ethanol, respectively) for 1 h prior to the addition of Ang1 (10 nM) for an additional 23 h. Treatment with both inhibitors (AACOCF 3 and scalaradial) did not modulate Ang1 pro-survival activity on neutrophils (data not shown).
Additive effect of IL-8 and Ang1 on neutrophil viability
We reported that both angiopoietins can potentiate IL-8-induced neutrophil migration [24] and since IL-8 is a neutrophil pro-survival mediator [54] , we wanted to assess if the angiopoietins and IL-8 could cooperate on neutrophil viability. First, we addressed the capacity of IL-8 to promote neutrophil viability. Upon a 24-hour incubation period, we observed a bell-shape concentration-dependent anti-apoptotic effect of IL-8 (5-200 nM) on neutrophil viability with an optimal effect being achieved at 25 nM, providing a 34% increase of neutrophil viability (raising the basal viability from 43.4 to 58.0%) (Suppl. data Fig. 2 ). Neutrophils were then treated with Ang1 (0.1-10 nM) in the presence or absence of IL-8 (25 nM) for 24 h. The combination of IL-8 (25 nM) with Ang1 (10 nM) provided an additive effect, increasing basal neutrophil viability by 56%. This combination provided also a significant increase of neutrophil viability as compared to cells treated with Ang1 (10 nM) alone ( Fig. 6 ). Neutrophils were also treated with Ang1 (0.1 nM) to assess whether IL-8 (25 nM) could prime an effect of Ang1 at a concentration, which by itself, does not provide a significant effect on neutrophil viability (Fig. 6 ). In addition, IL-8 or Ang1-treated neutrophils had a significant decrease of cell apoptosis, which was also significant upon the combination of IL-8 (25 nM) and Ang1 (10 nM) ( Fig. 6 ). Finally, treatment of the neutrophils with IL-8 (25 nM) and Ang1 (10 nM), alone or combined, led to a significant decrease of cell necrosis (Fig. 6 ).
Contribution of IL-8 on Ang1 pro-survival activity
Both angiopoietins are known to promote similar pro-inflammatory activities in neutrophils [22, 24] . However, in our current set of experiments, we demonstrate differential activities of Ang1 and Ang2 on neutrophil viability. In addition, we recently observed that Ang1, but not Ang2, induces IL-8 synthesis and release from neutrophils in a concentration-dependent manner with an optimal effect at 10 nM and within 2 h post-stimulation [77] . Therefore, we wanted to address whether IL-8 was implicated in Ang1-induced neutrophil viability. Neutrophils were pretreated with goat anti-human IL-8 blocking IgG antibodies (20-100 μg/ml) or control goat IgG isotype (100 μg/ml) for 2 h before stimulation with PBS, IL-8 (25 nM) or Ang1 (10 nM) for an additional 22 h. Treatment with control goat IgG or with anti-IL-8 blocking antibodies (100 μg/ml) had no effect on basal neutrophil viability (Fig. 7) . Pretreatment with anti-IL-8 blocking antibodies reduced both IL-8 (25 nM) and Ang1 (10 nM)-induced neutrophil viability in a concentration-dependent manner with a maximal effect at 100 μg/ml for IL-8 (92% decrease) and 50 μg/ml for Ang1 (81% decrease) (Fig. 7) . In addition, treatment with IL-8 significantly decreased both apoptotic and necrotic neutrophils, whereas pretreatment with anti-IL-8 blocking antibodies (100 μg/ml) provided a trend to reverse the effect of IL-8 on neutrophil apoptosis, and significantly reversed the effect of IL-8 on neutrophil necrosis. Similarly, Ang1 also decreased significantly neutrophil apoptosis and necrosis, whereas pretreatment with anti-IL-8 blocking antibodies (50 and 100 μg/ml) significantly reversed only the effect of Ang1 on neutrophil necrosis while having a trend to reverse the effect of Ang1 on neutrophil apoptosis (Fig. 7) .
Contribution of IL-8 on PAF pro-survival activity
Since Ang1 and PAF are both capable to promote IL-8 synthesis and release by the neutrophils [77] , and that Ang1 pro-survival activity is IL-8-dependent, we thus wanted to address if PAF pro-survival activity is also IL-8-dependent. Neutrophils were pretreated with goat anti-human IL-8 blocking IgG antibodies (20-100 μg/ml) or control goat IgG isotype (100 μg/ml) for 2 h before stimulation with PBS or PAF (100 nM) for an additional 22 h. Treatment with control goat IgG or with anti-IL-8 blocking antibodies (100 μg/ml) had no effect on basal neutrophil viability ( Fig. 8) . Pretreatment with anti-IL-8 blocking antibodies (20, 50 and 100 μg/ml) reduced significantly PAF-induced neutrophil viability in a concentration-dependent manner with a maximal effect at 100 μg/ml (92% decrease) ( Fig. 8) . In addition, treatment with PAF significantly decreased both apoptotic and necrotic neutrophils, whereas pretreatment with anti-IL-8 blocking antibodies (20, 50 and 100 μg/ml) provided a trend to reverse the effect of PAF on neutrophil apoptosis, and significantly reversed the effect of PAF on neutrophil necrosis (Fig. 8 ).
Neutrophil chemotactic activity
We previously reported the capacity of Ang1 and IL-8 to promote neutrophil migration [24] . Herein, we wanted to ascertain if the neutrophils upon a 24-hour incubation period either under PBS or Ang1 treatment were still capable to migrate upon stimulation by pro-chemotactic mediators such as IL-8 and fMLP. On freshly isolated neutrophils, IL-8 (25 nM) [24] increased by 6.3-fold the migration of neutrophils upon a 60-minute incubation period. Similarly, a treatment with fMLP (0.1-10 μM) [78, 79] provided a bell-shaped increase of neutrophil migration with a peak mediated at 1 μM (13.9-fold) ( Fig. 9 ). Upon a 24-hour incubation period in control media containing either control vehicle (PBS) or Ang1 (10 nM), we performed a 60-minute chemotactic assay and observed that the neutrophils maintained a similar capacity to respond to IL-8 (7.8-and 6.5-fold of increase respectively) and fMLP (1 μM; 9.3-and 8.1-fold of increase respectively) ( Fig. 9 ).
Discussion
In the present study, we report for the first time that upon Tie2 activation, Ang1 has a pro-survival activity on neutrophils, whereas Ang2 has no effect. The combination of known pro-inflammatory and prosurvival mediators for the neutrophils, namely PAF and IL-8, provided an additive effect on Ang1-mediated pro-survival activity. In addition, using a selective PAF receptor antagonist and blocking IL-8 antibodies, we delineated that Ang1 pro-survival activity is IL-8 dependent. 
Differential effects of Ang1 and Ang2 on neutrophil viability
Ang1 and Ang2 have been reported to promote differential activities; Ang1 being recognized as a Tie2 receptor agonist, supporting the maturation and the stabilization of the neovessels, while Ang2 was recognized as an antagonist, promoting vascular permeability and the regression of pre-existing vasculature [3, 4, 14, 15] . However, under specific conditions, Ang2 can also act as a Tie2 agonist by supporting Tie2 phosphorylation and associated downstream biological activities [16] [17] [18] [19] . For instance, in ECs, Ang1 is recognized to inhibit apoptosis through the activation of PI3K/Akt and ERK1/2 pathways, which cooperate to prevent pro-apoptotic caspase-3, -7, and -9 activation [10, 11] . For Ang2, the data are less clear; some groups reported that Ang2 has pro-apoptotic activities [55, 56] , whereas others reported that Ang2 could promote EC survival through the activation of ERK1/2 and PI3K pathways [17, 57] . In addition, we reported that both angiopoietins share common agonistic pro-inflammatory activities, namely, on their capacity to promote endothelial PAF synthesis and P-selectin translocation [20] [21] [22] . In neutrophils, we reported the expression of Tie2 receptor, and the capacity of both angiopoietins to induce PAF synthesis, CD11/CD18 (β 2 -integrin) activation, neutrophil adhesion and migration [22, 24] . This latter effect was also confirmed by an independent group [65] . In addition, considering that both angiopoietins can modulate EC viability and induce the synthesis and release of a neutrophil pro-survival mediator, namely PAF [10, 11, 17, 22, 42, [55] [56] [57] , we were led to address the capacity of both angiopoietins to modulate neutrophil viability, and if so, define the role of PAF in that process.
In the current study, we performed a concentration-and timedependent assay, and observed that Ang1 is providing a pro-survival activity on the neutrophils by delaying the entry of cells into apoptotic and necrotic phases, while Ang2 had no significant effect on basal viability. In addition, we observed that Ang1/Tie2 interaction is needed to support Ang1 pro-survival activity, as a pretreatment with selective blocking anti-human Tie2 antibodies, almost completely abrogated (≈85%) Ang1 pro-survival activity in neutrophils. The residual effect could be due to an incomplete blockade of Tie2 receptor by the selective antibodies, thus, allowing partial Ang1/Tie2 interaction and biological activity. Another possibility could be that Ang1 can induce some biological activities upon its binding to specific integrins, independently from Tie2 participation [9, 80, 81] . If so, then it appears that Ang1/integrin interaction would have a minor contribution on Ang1 pro-survival activity.
Cooperation and contribution of PAF and IL-8 on Ang1-mediated pro-survival activity
In addition to the differential capacity of Ang1 to prolong the viability of the neutrophils, as opposed to Ang2, we recently observed another differential effect between Ang1 and Ang2 on neutrophils. Indeed, we reported that Ang1 (but not Ang2) promotes IL-8 synthesis and release from neutrophils [77] . Since IL-8 is a pro-survival mediator for the neutrophils [54] , we hypothesized that the synthesis and/ or the release of IL-8, might as well, like endogenous PAF supports the pro-survival activity of Ang1 on neutrophils. Our data demonstrate that a combination of PAF or IL-8 with Ang1 produced an additive effect on neutrophil viability. These results are in agreement with previous studies demonstrating that under in vivo pro-inflammatory environments, different mediators can cooperate to increase neutrophil viability, thereby delaying their entry into apoptotic phase, even up to several days [26] and thus, resulting in an enhanced inflammatory state which can become pathological [29] .
To delineate the contribution of PAF on Ang1 pro-survival activity in neutrophils, we addressed the effect of a selective PAF receptor antagonist (BN 52021) [67, 68] on Ang1 anti-apoptotic activity. Treatment with BN 52021 did not modulate basal neutrophil viability, whereas it was efficient to prevent pro-survival activity mediated by exogenous PAF. In addition, in pretreatment, BN 52021 did not inhibit Ang1 pro-survival activity on neutrophils, thus, suggesting that Ang1 anti-apoptotic activity is PAF-independent. We previously reported that Ang1 and Ang2 could induce PAF synthesis from ECs through the activation of sPLA 2 -V, and independently from cPLA 2 participation [21] . We also observed that both angiopoietins could promote neutrophil PAF synthesis [22] . In neutrophils, both cPLA 2 and sPLA 2 -V are expressed and can contribute to PAF synthesis in function of the stimuli [69, [71] [72] [73] . Thereby, we addressed the effect of selective inhibitors of the secreted and cytosolic form of PLA 2 on Ang1mediated pro-survival activity on neutrophils. Pretreatment of neutrophils either with the cPLA 2 inhibitor [74] [75] [76] , AACOCF 3 , or the sPLA 2 inhibitor [74, 75, 82] , scalaradial, did not reduce Ang1 prosurvival activity on neutrophils. Consequently, if both angiopoietins (Ang1 and Ang2) can support the endogenous PAF synthesis from neutrophils [22] , the concentration of PAF synthesized is not sufficient to participate to Ang1-mediated pro-survival activity on the neutrophils.
Since PAF cannot be considered as the pro-inflammatory mediator supporting Ang1-mediated pro-survival activity, we thus addressed whether IL-8 release was implicated in Ang1-induced neutrophil viability. Under basal condition, there is no or marginal release of IL-8 by the neutrophils, and a treatment with an anti-human IL-8 blocking antibodies did not modulate the basal survival rate. However, in pretreatment to Ang1-stimulation, the anti-IL-8 blocking antibodies provided a marked reduction (≈80%) of Ang1 pro-survival effect. Consequently, these data are supporting our hypothesis that the synthesis and release of IL-8 plays a pivotal role as a discriminating factor for the differential capacity of Ang1, as opposed to Ang2, to support neutrophil viability. The incomplete reduction of Ang1-mediated pro-survival activity following a pretreatment with IL-8 blocking antibodies could suggest that Ang1 can activate downstream signaling pathways capable to provide pro-survival/anti-apoptotic activities, and/or that Ang1 is capable to promote the release of other prosurvival mediators.
We also reported that PAF is capable to promote IL-8 synthesis and release by the neutrophils [77] . Since a treatment with exogenous PAF is capable to promote neutrophil viability, we addressed the contribution of IL-8 on PAF pro-survival activity. By pretreating the neutrophils with anti-IL-8 blocking antibodies, we observed an obliteration of PAF anti-apoptotic activity. These latter observations demonstrate that the synthesis and release of IL-8 upon a stimulation of neutrophils either with exogenous Ang1 or PAF is the common factor responsible for their pro-survival activity.
It is well defined that transvascular migrated neutrophils are playing a major role in the development of pathological inflammation by prolonging their survival half-life, thus, extending their capacity to promote the synthesis and release of pro-inflammatory mediators, cytokines and metalloproteinases [28, 29, [83] [84] [85] . We and other groups reported the chemotactic activity of Ang1 and other cytokines on freshly isolated neutrophils [24, 65, 86] . Herein, we observed that a treatment of the neutrophils with Ang1 under acute or prolong time period did not alter the capacity of the neutrophils to migrate upon their stimulation by chemotactic mediators, such as fMLP and IL-8.
Previous studies reported that under in vitro conditions, Ang1 possesses anti-inflammatory properties. Ang1 reduces VEGF-induced leukocyte adhesion onto HUVEC and E-selectin expression [87] and thrombin-mediated neutrophil adhesion onto EC [88] . Other studies reported that under in vivo conditions, Ang1 has an antiinflammatory role as observed in acute lung injury, endotoxic shock and cardiac remodeling [12, 13, 89] . Similarly, the genetic overexpression or overexpression following infection with adenovirus carrying the Ang1 gene did protect the vasculature from VEGF and irritantinduced leakage in mice [4, 90] . On the other hand, we and other groups reported that under in vitro conditions Ang1 can have pro-inflammatory activities [20] [21] [22] 24, 65, 77, 91] . In addition, it has also been reported that the administration of Ang1 did not inhibit VEGFinduced vascular permeability but delayed edema resolution, thus suggesting that Ang1 is not a universal inhibitor of EC permeability as previously thought [18] . Together, these observations could suggest that Ang1 may have differential biological activities in function of the biological conditions and environment.
In summary, our study is the first one to report that Ang1, upon its binding to Tie2 receptor, is providing a pro-survival activity on neutrophils, as opposed to Ang2, which has no effect. In addition, Ang1 pro-survival activity is mainly driven by its capacity to promote the synthesis and release of IL-8 by the neutrophils. However, additional studies will be needed to delineate which intracellular signaling pathways are participating in the induction of Ang1 pro-survival and antiapoptotic activities on neutrophils. Together, our data provides novel insight in the capacity of Ang1 to prolong neutrophil viability and to promote the release of pro-inflammatory mediators, which could contribute to support the development of pathological vascular diseases associated to inflammatory response.
Supplementary data to this article can be found online at doi:10. 1016/j.bbamcr.2011.12.002.
Abbreviations
Ang1
angiopoietin-1 Ang2
angiopoietin-2 ARDS acute respiratory distress syndrome cPLA 2 cytosolic phospholipase A 2 EC endothelial cell FITC fluorescein isothiocyanate fMLP formyl-Methionyl-Leucyl-Phenylalanine IL-8 interleukin-8 MAPK mitogen-activated protein kinase PAF platelet activating factor P.I. propidium iodide PKC protein kinase C SIRS systemic inflammatory response syndrome sPLA 2 secreted phospholipase A 2 TNF-α tumor necrosis factor-α VEGF vascular endothelial growth factor
